Whitefish, MT / July 25, 2014 / Premier Biomedical Inc. (OTC: BIEI), a biopharmaceutical company focused on developing and commercializing innovative therapies targeting cancer, traumatic brain injury, Alzheimer’s disease, MS and other serious conditions, recently announced that the William Beaumont Army Medical Center (“WBAMC”) has begun drafting a protocol that it plans to submit to their Institutional Review Board overseeing its double-blind clinical trial of Feldetrex(tm) in mid-August.
“We are looking forward to working with the Army in these trials,” said Premier Biomedical Inc. President & CEO William Hartman. “We believe that both of our technologies, Feldetrex(tm) medication for pain relief as well as our core technology to ‘Physically remove the pathophysiological basis of the disease(tm) will be of immense benefit to patients … I am particularly happy that we have the chance to work with the Army to advance these technologies and bring relief to our wounded warriors and to the general population.”
Premier Biomedical, in conjunction with the WBAMC, plan to initially conduct a clinical trial of Feldetrex(tm) pain medication, followed by a separate, second clinical trial of Premier Biomedical’s core technology designed to physically remove the pathophysiological basis of the disease. In the first double-blind study of the medication, patients will receive either a placebo, Lyrica(r), Feldetrex(tm), and a Lyrica-Feldetrex(tm) blend at the William Beaumont Army Medical Center.
Pfizer Inc.’s (NYSE: PFE) Lyrica(r) is a leading drug designed to treat nerve and muscle pain caused by diabetes, shingles, fibromyalgia, or spinal cord injury, as well as a treatment for partial-onset seizures in adults. With over $4.5 billion in annual sales, Lyrica(r) has become a standard of care for pain relief. Capturing just a faction of that market with Feldetrex(tm) could generate significant top-line revenue.
In the second clinical trial, Premier Biomedical plans to demonstrate that its process of removing malevolent molecular compounds that cause clinical depression, leading to suicide/homicide ideation is effective in individual soldiers suffering from PTSD and/or traumatic brain injury. The company has already demonstrated that its process is effective in removing the malevolent molecular compounds from pooled cerebral spinal fluid furnished by the WBAMC. Management anticipates that removing these compounds from the cerebral spinal fluid of individual patients suffering from TBI or PTSD will represent another major step forward in the successful treatment of these serious conditions.
Management also recently secured 20 of 24 claims in its broadest patent application to “physically remove the pathophysiological basis of disease”, which sets the stage to study roughly 19 diseases that are either incurable or difficult to cure using traditional therapies. If these claims translate to successful clinical trials, the company would be solving one of the Army’s largest medical issues.
Premier Biomedical has a number of other programs in the works aside from its two upcoming clinical trials. In January, management participated in a head trauma sports symposium and met important representatives from the NFL, NCAA, NFL Retired Players Association, and other groups. And in April, the company presented its animal study on breast cancer at the American Association for Cancer Research. The therapy used in the breast cancer study is based on the same underlying monoclonal antibody as Bristol-Myers’ (NYSE: BYM) highly successful Yervoy.
Investors may want to take a closer look at the company given its numerous upcoming catalysts. With two clinical trials about to begin and ongoing negotiations with other parties, management could be on the cusp of unlocking significant value for shareholders, particularly given its partnerships with the DoD and UTEP.
For more information, see the following resources:
Get Updates on Premier Biomedical here: http://www.tdmfinancial.com/emailassets/biei/biei_landing.php
Disclosure: Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx